Bruna Costa Zorzanelli

Bruna Costa Zorzanelli

Auto-generated profile, based on publicly available information

Bruna Costa Zorzanelli

Universidade Estácio de Sá, Campus Niterói Niterói RJ Brazil

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2026 in Chemical Biology & Drug Design
Verified
Journal Article
Open access
CRCaroline Rodrigues Chaves dos Reis
Caroline Rodrigues Chaves dos Reis
HSHellen Valério Chaves Moura de Souza
Hellen Valério Chaves Moura de Souza
LPLidia Corrêa Parra
Lidia Corrêa Parra
GSGuilber Valério Chaves Moura de Souza
Guilber Valério Chaves Moura de Souza
BZBruna Costa Zorzanelli
Bruna Costa Zorzanelli
TFTACIO VINICIO AMORIM FERNANDES
TACIO VINICIO AMORIM FERNANDES
Over three decades, cruzain, the principal cysteine protease of Trypanosoma cruzi and a validated drug target for Chagas disease, has accumulated 215 inhibitors with IC 50 ≤ 1 μM, more than 30 crystal structures, and no clinical candidates. This review argues that the resulting translational paradox reflects not target invalidity, but a persistent strategic mismatch between how cruzain inhibitors have been optimised and what intracellular efficacy requires. Across peptidyl vinyl sulfones, non‐peptidic scaffolds, and thiosemicarbazones, enzymatic potency has been systematically prioritised over the coupled determinants of intracellular exposure: permeability, metabolic stability, and cathepsin selectivity. Each inhibitor class fails for a distinct proximal reason, and these failures converge on the same optimisation bias. Computational approaches (docking, molecular dynamics, free‐energy perturbation and machine‐learning QSAR) have been applied with increasing sophistication, but against affinity‐centred objectives that underrepresent exposure constraints. As its principal contribution, this work proposes a multiparametric optimisation framework, provisional viability benchmarks, and a feasibility‐envelope concept that reframes cruzain inhibitor discovery as a constraint‐satisfaction rather than a potency‐maximisation problem. The framework outlines provisional quantitative criteria that a next‐generation cruzain lead would likely need to satisfy and explains why structurally tractable intracellular cysteine protease targets can remain clinically unrealised.

6 October 2026 in Molecular Simulation
Verified
Journal Article
Closed access
TFTACIO VINICIO AMORIM FERNANDES
TACIO VINICIO AMORIM FERNANDES
FBFrederico Silva Castelo Branco
Frederico Silva Castelo Branco
VPVinícius Santos De Pontes
Vinícius Santos De Pontes
BZBruna Costa Zorzanelli
Bruna Costa Zorzanelli
MBMonica Macedo Bastos
Monica Macedo Bastos
LHLucas Villas Bôas Hoelz
Lucas Villas Bôas Hoelz